Composition for improving efficacy of L-DOPA treatment

A method for (a) treating impaired motor skills in a mammal suffering from Parkinson's Disease;

• (b) improving the efficacy of levodopa (L-DOPA) in treatment of impaired motor skills in a mammal suffering from Parkinson's Disease (PD);
• and/or (c) reducing L-DOPA associated involuntary movements selected from the group consisting of choreiform, dystonic and dyskinetic movements, in the treatment of impaired motor skills in a mammal suffering from Parkinson's Disease, the method comprising administering to the mammal therapeutically effective amount of L-DOPA to yield a synergy with a composition comprising therapeutically effective amounts of:
• (i) at least one of uridine and cytidine, or salts, phosphates, acylated forms or esters thereof;
• (ii) at least one of docosahexaenoic acid (22:6;
• DHA), eicosapentaenoic acid (20:5;
• EPA) and docosapentaenoic acid (22:5;
• DPA);
• (iii) choline, or salts or esters thereof;
• and
• (iv) at least one vitamin B selected from the group consisting of vitamins B6, B9 and B12, wherein the dosage of administered L-DOPA is reduced compared to the dosage of L-DOPA if the composition is not co-administered.